Virtual Cell platforms are emerging as a transformative capability for drug discovery and development, enabling faster, more cost-efficient, and more productive R&D pipelines. By virtualizing biological experiments with AI-driven models, Virtual Cells allow researchers to simulate millions of perturbations in silico, far beyond what is feasible in the laboratory, while increasing the probability of success for downstream investment decisions.
At their core, Virtual Cells aim to capture a systems-level understanding of biology from today’s fragmented but rapidly expanding data landscape. By reducing reliance on slow, expensive, and often poorly translatable wet lab experimentation, they offer pharma and biotech a path towards smarter, leaner, and more scalable R&D models. Importantly, Virtual Cells are not intended to replace experimentation, but to refocus it, shifting lab work from broad hypothesis generation to targeted validation of the most promising, mechanistically grounded hypotheses.